These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 15309748)

  • 1. Triple-nucleoside regimens versus efavirenz.
    Maida I; Nuñez M; Soriano V
    N Engl J Med; 2004 Aug; 351(7):717-9; author reply 717-9. PubMed ID: 15309748
    [No Abstract]   [Full Text] [Related]  

  • 2. Triple-nucleoside regimens versus efavirenz.
    De Luca A; Di Giambenedetto S
    N Engl J Med; 2004 Aug; 351(7):717-9; author reply 717-9. PubMed ID: 15306677
    [No Abstract]   [Full Text] [Related]  

  • 3. Triple-nucleoside regimens versus efavirenz-containing regimens for the initial treatment of HIV-1 infection.
    Gulick RM; Ribaudo HJ; Shikuma CM; Lustgarten S; Squires KE; Meyer WA; Acosta EP; Schackman BR; Pilcher CD; Murphy RL; Maher WE; Witt MD; Reichman RC; Snyder S; Klingman KL; Kuritzkes DR;
    N Engl J Med; 2004 Apr; 350(18):1850-61. PubMed ID: 15115831
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efavirenz plus zidovudine and lamivudine, efavirenz plus indinavir, and indinavir plus zidovudine and lamivudine in the treatment of HIV-1 infection in adults. Study 006 Team.
    Staszewski S; Morales-Ramirez J; Tashima KT; Rachlis A; Skiest D; Stanford J; Stryker R; Johnson P; Labriola DF; Farina D; Manion DJ; Ruiz NM
    N Engl J Med; 1999 Dec; 341(25):1865-73. PubMed ID: 10601505
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A new HAART on the horizon says the proof is in the potency.
    AIDS Alert; 1999 Apr; 14(4):37-9. PubMed ID: 11366218
    [TBL] [Abstract][Full Text] [Related]  

  • 6. An open-label, randomized comparative pilot study of a single-class quadruple therapy regimen versus a 2-class triple therapy regimen for individuals initiating antiretroviral therapy.
    Moyle G; Higgs C; Teague A; Mandalia S; Nelson M; Johnson M; Fisher M; Gazzard B
    Antivir Ther; 2006; 11(1):73-8. PubMed ID: 16518962
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efavirenz in HIV infection.
    Casado JL; Moreno S
    N Engl J Med; 2000 Apr; 342(17):1290-1. PubMed ID: 10787332
    [No Abstract]   [Full Text] [Related]  

  • 8. Abacavir versus zidovudine combined with lamivudine and efavirenz, for the treatment of antiretroviral-naive HIV-infected adults.
    DeJesus E; Herrera G; Teofilo E; Gerstoft J; Buendia CB; Brand JD; Brothers CH; Hernandez J; Castillo SA; Bonny T; Lanier ER; Scott TR;
    Clin Infect Dis; 2004 Oct; 39(7):1038-46. PubMed ID: 15472858
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Anatomy of a study: Trizivir vs. Sustiva.
    Berger DS
    Posit Aware; 2003; 14(3):40-1. PubMed ID: 12866492
    [No Abstract]   [Full Text] [Related]  

  • 10. A new approach to initial antiretroviral therapy: protease-sparing combination regimens.
    Hanna L
    BETA; 1998 Oct; ():9-13. PubMed ID: 11365999
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Nelfinavir, efavirenz, or both after the failure of nucleoside treatment of HIV infection.
    Albrecht MA; Bosch RJ; Hammer SM; Liou SH; Kessler H; Para MF; Eron J; Valdez H; Dehlinger M; Katzenstein DA;
    N Engl J Med; 2001 Aug; 345(6):398-407. PubMed ID: 11496850
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Triple nucleoside reverse transcriptase inhibitor- vs. nonnucleoside reverse transcriptase inhibitor-containing regimens as first-line therapy: efficacy and durability in a prospective cohort of French HIV-infected patients.
    Cuzin L; Pugliese P; Bugnon F; Delpierre C; Cua E; Billaud E; Massip P; Raffi F; Dellamonica P
    HIV Med; 2005 Nov; 6(6):388-95. PubMed ID: 16268820
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Report from the XVI International AIDS Conference. Efavirenz for high viral load and low CD4--a secondary analysis of ACTG 5095.
    Feinberg J
    AIDS Clin Care; 2006 Nov; 18(11):99. PubMed ID: 17183745
    [No Abstract]   [Full Text] [Related]  

  • 14. [Valuable combination partner. Great benefit for therapy naive patients].
    MMW Fortschr Med; 2004 Apr; 146 Spec No 1():82-4. PubMed ID: 15373061
    [No Abstract]   [Full Text] [Related]  

  • 15. Meeting notes from the 2nd International AIDS Society Conference on HIV Pathogenesis and Treatment. Trizivir vs. efavirenz: results from ACTG 5095.
    Feinberg J
    AIDS Clin Care; 2003 Sep; 15(9):78-9. PubMed ID: 14669723
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Review of NNRTIs: 'today and tomorrow'.
    Katlama C
    Int J Clin Pract Suppl; 1999 Jun; 103():16-20. PubMed ID: 10622038
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A comparison of three initial antiretroviral AIDS regimens.
    Ribaudo HJ; Kuritzkes DR; Gulick RM
    N Engl J Med; 2007 Sep; 357(10):1056-7. PubMed ID: 17804858
    [No Abstract]   [Full Text] [Related]  

  • 18. [HIV infection: DuPont Pharma presents the results of its antiretroviral agent].
    Allerg Immunol (Paris); 1998 Apr; 30(4):123-4. PubMed ID: 9631694
    [No Abstract]   [Full Text] [Related]  

  • 19. [Nucleoside analogs inhibiting reverse transcriptase: use in adult patient with HIV infection].
    Aguirrebengoa K; Mallolas J; Uriz J; Torres Tortosa M
    Enferm Infecc Microbiol Clin; 1996 Oct; 14 Suppl 1():3-9. PubMed ID: 9053024
    [No Abstract]   [Full Text] [Related]  

  • 20. New drugs on the horizon.
    Proj Inf Perspect; 1998 Apr; (24):10-3. PubMed ID: 11365712
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.